Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)
| Market Cap | 5.87B+98.9% |
| Revenue (ttm) | n/a+58.9% |
| Net Income | n/a+1583.9% |
| EPS | n/a+2350.0% |
| Shares Out | 76.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 116,097.666 |
| Open | 77.18 |
| Previous Close | 77.96 |
| Day's Range | 75.53 - 77.38 |
| 52-Week Range | 35.20 - 82.94 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 86.40(+12.22%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About KNSA
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$KNSA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in KNSA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KNSA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KNSA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New KNSA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KNSA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KNSA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $103.96M |
| IWMiShares Russell 2000 ETF | $93.34M |
| VBVanguard Morningstar Small-Cap ETF | $75.35M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $43.39M |
| IWOiShares Russell 2000 Growth ETF | $33.32M |
| DFASDimensional - US Small Cap ETF | $24.69M |
Estimated from each fund’s disclosed top holdings × AUM
KNSA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from KNSA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score